Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-25 @ 2:34 AM
Ignite Modification Date: 2025-12-26 @ 1:10 AM
NCT ID: NCT01269034
Description: While Adverse Events were monitored/assessed, none were observed
Frequency Threshold: 0
Time Frame: 6 years
Study: NCT01269034
Study Brief: New Onset Type 1 Diabetes: Role of Exenatide
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
Part A Exenatide and long acting insulin before the boost. Exenatide: 1.25 mcg before the boost sub-cutaneously. 0 None 0 1 0 1 View
Part C long acting insulin+ rapid acting+1.25 mcg Exenatide before the boost long acting insulin + rapid acting + 1.25 mcg Exenatide: Depends on their body needs. 0 None 0 1 0 1 View
Healthy Controls healthy controls without any medication before the boost. 0 None 0 9 0 9 View
Part B Rapid and long acting insulin before the boost Rapid and long acting insulin: Depends on their Carbohydrate ratio and body needs 0 None 0 2 0 2 View
Serious Events(If Any):
Other Events(If Any):